CERO - היקף יתרות המזומנים של החברה cero.bio

סמל תאגידי ולוגו של CERo Therapeutics (CERO)

CERo Therapeutics (CERO) business efficiency is based on patent licensing, which reduces costs and strengthens cash flow. Cash asset dynamics confirm financial stability, with the indicator currently at 0.00. The company's growth depends on scientific breakthroughs rather than economic cycles. The current focus has shifted toward intellectual property protection and safe early-stage immunotherapy trials.

CERo Therapeutics Holdings - יתרת המזומנים של החברה CERO (תקופה 21.02.2024 - 08.11.2025)

פילוחי מדדים פיננסיים ומדדי שוק עבור CERo Therapeutics (CERO)

- פרטי פוזיציית מזומנים ותזרימי מזומנים:
ניתוח כל מדדי החברה:CERO CERo Therapeutics
פריט של המותג CERo Therapeutics Holdings Inc.

This indicator captures the total volume of liquid assets held by the company as of the reporting date. The trend of this resource determines the issuer's ability to service its obligations without incurring external debt. By analyzing the free cash flow metric, an investor assesses the risk of default or excessive capital freezing. For CERo Therapeutics (CERO), such liquidity is critical when financing the development of T-cell therapy. A sufficient cash reserve guarantees the uninterrupted creation of safe engineered cells to combat tumors.